Form 4: Jasper Therapeutics Director Granted 7,500 Stock Options

Jasper Therapeutics, Inc. Director Vishal Kapoor was granted options to purchase 7,500 shares of common stock at an exercise price of $6.77 per share, effective July 3, 2025.

Summary

• Vishal Kapoor, a Director of Jasper Therapeutics, Inc. (JSPR), was granted stock options.
• The grant is for the right to purchase 7,500 shares of Voting Common Stock.
• The exercise price for these options is $6.77 per share.
• The transaction date, which is also the grant date, is July 3, 2025.
• These options become exercisable on July 3, 2026, and expire on July 3, 2035.
• The grant was made automatically under the Issuer's Non-Employee Director Compensation Policy, which provides for such grants on the date of each annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive event, aligning management incentives with shareholder interests and reflecting standard corporate governance practices. It does not indicate any negative operational or financial news.

Positives

• The grant of stock options aligns the interests of Director Vishal Kapoor with those of shareholders, incentivizing long-term company performance.
• The automatic nature of the grant, pursuant to a compensation policy, indicates a structured and transparent approach to director remuneration.

Future Outlook

The document does not provide a future outlook or guidance beyond the specific terms of the stock option grant, such as its exercisable and expiration dates.

Management Comments

• Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders.

Industry Context

The grant of stock options to non-employee directors is a common practice across various industries, including biotechnology and pharmaceuticals, serving as a standard component of executive and director compensation packages to align leadership interests with shareholder value creation.

Comparison to Industry Standards

• Granting stock options to non-employee directors is a standard compensation practice in publicly traded companies, particularly within the biotechnology sector, to incentivize long-term performance and retention.
• The specific number of shares (7,500) and exercise price ($6.77) would typically be benchmarked against peer companies of similar market capitalization and stage of development, though specific comparable companies or projects are not detailed in this filing.
• The structure, including a one-year vesting period (exercisable date one year after grant) and a ten-year expiration, is also common for such equity awards.

Corporate Governance

Related Party Transactions

• The grant of 7,500 stock options to Vishal Kapoor, a Director of Jasper Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.

Next Steps

• The stock options granted to Director Vishal Kapoor will become exercisable on July 3, 2026.
• The options will remain valid until their expiration date of July 3, 2035.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Form 4, SEC filing, stock options, director compensation, beneficial ownership, equity grant, Vishal Kapoor